One approach for improving recommendations based on tumor-only sequencing is use of a multidisciplinary genomic tumor board, in which researchers from a variety of backgrounds weigh in on the best way to interpret test results.
The rate of grade 3/4 adverse events was higher for patients with resected pancreatic adenocarcinoma treated with adjuvant mFOLFIRINOX versus gemcitabine.
A universal cancer gene therapy from the early 2000s is headed into phase 2 trials, in light of renewed interest and outlier patients who are still alive at 10 years later.
The median duration of response to olaparib in these patients with metastatic pancreatic cancer was more than 2 years.
Many patients with noncurable pancreatic adenocarcinoma do not have a specialized cancer consultation and most do not receive cancer-directed therapy.
Twitter is increasingly being used by oncologists as a tool to communicate advancements in in the treatment of cancer. What could go wrong?
Basket trials are those that test investigational therapies in patients who have different types of cancer but share a particular genomic aberration.
Full adoption of biosimilars will require proper provider and patient education, payer coverage navigation support, and streamlined workflows.
Organoids created from tumor samples have been revolutionizing laboratory research, but they also may begin helping oncologists decide on treatment regimens for patients.
With the rising rates of cancer diagnosis and increasing cost of treatment, delays in time to treatment initiation can be seen as primarily policy related.
